Anzurstobart, a fully human monoclonal anti-SIRPα antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPα interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications.